GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » Return-on-Tangible-Asset

PaxMedica (PaxMedica) Return-on-Tangible-Asset : -344.62% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is PaxMedica Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PaxMedica's annualized Net Income for the quarter that ended in Mar. 2024 was $-14.77 Mil. PaxMedica's average total tangible assets for the quarter that ended in Mar. 2024 was $4.29 Mil. Therefore, PaxMedica's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -344.62%.

The historical rank and industry rank for PaxMedica's Return-on-Tangible-Asset or its related term are showing as below:

PXMD' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -3523.53   Med: -1153.86   Max: -418.1
Current: -418.1

During the past 6 years, PaxMedica's highest Return-on-Tangible-Asset was -418.10%. The lowest was -3523.53%. And the median was -1153.86%.

PXMD's Return-on-Tangible-Asset is ranked worse than
95.87% of 1550 companies
in the Biotechnology industry
Industry Median: -40.295 vs PXMD: -418.10

PaxMedica Return-on-Tangible-Asset Historical Data

The historical data trend for PaxMedica's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PaxMedica Return-on-Tangible-Asset Chart

PaxMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -3,523.53 -1,362.23 -1,153.86 -1,037.64 -463.98

PaxMedica Quarterly Data
Mar19 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -440.94 -281.81 -482.12 -531.30 -344.62

Competitive Comparison of PaxMedica's Return-on-Tangible-Asset

For the Biotechnology subindustry, PaxMedica's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PaxMedica's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PaxMedica's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where PaxMedica's Return-on-Tangible-Asset falls into.



PaxMedica Return-on-Tangible-Asset Calculation

PaxMedica's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-18.29/( (2.204+5.68)/ 2 )
=-18.29/3.942
=-463.98 %

PaxMedica's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-14.772/( (5.68+2.893)/ 2 )
=-14.772/4.2865
=-344.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


PaxMedica  (OTCPK:PXMD) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


PaxMedica Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of PaxMedica's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PaxMedica (PaxMedica) Business Description

Traded in Other Exchanges
N/A
Address
303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Executives
Zachary Rome director, officer: Chief Operating Officer C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Derby director, officer: Executive Chairman 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Howard J. Weisman director, officer: Chief Executive Officer C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle director 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho director 22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough officer: Chief Medical Officer C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc 10 percent owner 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon officer: Chief Financial Officer 2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748